{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:09:04Z","timestamp":1792195744688,"version":"4.4.0"},"reference-count":87,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.cca.2019.12.026","type":"journal-article","created":{"date-parts":[[2019,12,31]],"date-time":"2019-12-31T11:59:34Z","timestamp":1577793574000},"page":"45-53","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"special_numbering":"C","title":["Emerging biomarkers in Multiple Myeloma: A review"],"prefix":"10.1016","volume":"503","author":[{"given":"Nidhi","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9071-5426","authenticated-orcid":false,"given":"Aparna","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7761-5511","authenticated-orcid":false,"given":"Alpana","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.cca.2019.12.026_b0005","first-page":"7","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.cca.2019.12.026_b0010","doi-asserted-by":"crossref","first-page":"S147","DOI":"10.1016\/j.clml.2014.06.087","article-title":"Prognostic significance of quantifying circulating plasma cells in Multiple Myeloma","volume":"14","author":"Gonsalves","year":"2014","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"12","key":"10.1016\/j.cca.2019.12.026_b0015","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of Multiple Myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"issue":"26","key":"10.1016\/j.cca.2019.12.026_b0020","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: a report from international myeloma working group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.cca.2019.12.026_b0025","doi-asserted-by":"crossref","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple Myeloma","volume":"3","author":"Kumar","year":"2017","journal-title":"Nat. Rev. Dis. Primer."},{"issue":"26","key":"10.1016\/j.cca.2019.12.026_b0030","doi-asserted-by":"crossref","first-page":"6333","DOI":"10.1200\/JCO.2005.05.021","article-title":"Molecular pathogenesis and a consequent classification of Multiple Myeloma","volume":"23","author":"Bergsagel","year":"2005","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.cca.2019.12.026_b0035","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/MOH.0000000000000259","article-title":"Cell autonomous and microenvironmental regulation of tumor progression in precursor states of Multiple Myeloma","volume":"23","author":"Manier","year":"2016","journal-title":"Curr. Opin. Hematol."},{"issue":"5","key":"10.1016\/j.cca.2019.12.026_b0040","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrc3257","article-title":"The genetic architecture of Multiple Myeloma","volume":"12","author":"Morgan","year":"2012","journal-title":"Nat. Rev. Cancer"},{"issue":"25","key":"10.1016\/j.cca.2019.12.026_b0045","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1182\/blood-2015-06-650242","article-title":"Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?","volume":"126","author":"Chretien","year":"2015","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.cca.2019.12.026_b0050","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nrg3123","article-title":"Causes and consequences of aneuploidy in cancer","volume":"13","author":"Gordon","year":"2012","journal-title":"Nat. Rev. Genet."},{"issue":"3","key":"10.1016\/j.cca.2019.12.026_b0055","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/leu.2016.253","article-title":"Hyperhaploidy is a novel high-risk cytogenetic subgroup in Multiple Myeloma","volume":"31","author":"Sawyer","year":"2017","journal-title":"Leukemia"},{"issue":"21","key":"10.1016\/j.cca.2019.12.026_b0060","doi-asserted-by":"crossref","first-page":"4987","DOI":"10.1182\/blood.V116.21.4987.4987","article-title":"Multiple Myeloma: clinical implications of cytogenetic aberrations on selected plasma cells on conventional cytogenetics and interphase flourescence in situ hibridization (FISH)","volume":"116","author":"Verma","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.cca.2019.12.026_b0065","doi-asserted-by":"crossref","first-page":"235","DOI":"10.31557\/APJCP.2019.20.1.235","article-title":"Cytogenetic abnormalities in multiple myeloma patients at a tertiary healthcare center in India","volume":"20","author":"Govindasamy","year":"2019","journal-title":"Asian Pac. J. Cancer Prev. APJCP"},{"issue":"2","key":"10.1016\/j.cca.2019.12.026_b0070","doi-asserted-by":"crossref","first-page":"74","DOI":"10.4103\/ami.ami_42_18","article-title":"Chromosomal aberrations in Multiple Myeloma: A study on Indian population","volume":"5","author":"Royal","year":"2018","journal-title":"Acta Medica Int."},{"key":"10.1016\/j.cca.2019.12.026_b0075","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1039\/tf9373300524","article-title":"A new apparatus for electrophoretic analysis of colloidal mixtures","volume":"33","author":"Tiselius","year":"1937","journal-title":"Trans. Faraday Soc."},{"issue":"1","key":"10.1016\/j.cca.2019.12.026_b0080","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1084\/jem.69.1.119","article-title":"An electrophoretic study of immune sera and purified antibody preparations","volume":"69","author":"Tiselius","year":"1939","journal-title":"J. Exp. Med."},{"issue":"2","key":"10.1016\/j.cca.2019.12.026_b0085","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/1097-0142(195603\/04)9:2<262::AID-CNCR2820090210>3.0.CO;2-B","article-title":"Multiple-myeloma proteins. III. The antigenic relationship of Bence Jones proteins to normal gammaglobulin and multiple-myeloma serum proteins","volume":"9","author":"Korngold","year":"1956","journal-title":"Cancer"},{"key":"10.1016\/j.cca.2019.12.026_b0090","first-page":"207","article-title":"The nature of Bence-Jones proteins. Chemical similarities to polypetide chains of myeloma globulins and normal gamma-globulins","volume":"116","author":"Edelman","year":"1962","journal-title":"J. Exp. Med."},{"issue":"18","key":"10.1016\/j.cca.2019.12.026_b0095","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1182\/blood-2010-10-299529","article-title":"Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3","volume":"117","author":"Dimopoulos","year":"2011","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.cca.2019.12.026_b0100","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1182\/blood-2006-04-015784","article-title":"Immunoglobulin free light chains and solitary plasmacytoma of bone","volume":"108","author":"Dingli","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.cca.2019.12.026_b0105","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1055\/s-2001-12920","article-title":"Magnetic resonance and computed tomography imaging in Multiple Myeloma","volume":"5","author":"Lecouvet","year":"2001","journal-title":"Semin Musculoskelet Radiol."},{"issue":"1","key":"10.1016\/j.cca.2019.12.026_b0110","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ejrad.2005.01.017","article-title":"Role of MRI for the diagnosis and prognosis of Multiple Myeloma","volume":"55","author":"Baur-Melnyk","year":"2005","journal-title":"Eur. J. Radiol."},{"issue":"6","key":"10.1016\/j.cca.2019.12.026_b0115","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1200\/JCO.2014.57.9961","article-title":"Role of magnetic resonance imaging in the management of patients with Multiple Myeloma: a consensus statement","volume":"33","author":"Dimopoulos","year":"2015","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.cca.2019.12.026_b0120","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.2214\/ajr.184.4.01841199","article-title":"Value of FDG PET in the assessment of patients with Multiple Myeloma","volume":"184","author":"Bredella","year":"2005","journal-title":"AJR Am. J. Roentgenol."},{"issue":"4","key":"10.1016\/j.cca.2019.12.026_b0125","first-page":"218","article-title":"Evidence for cell adhesion-mediated drug resistance of Multiple Myeloma cells in vivo","volume":"21","author":"Schmidmaier","year":"2006","journal-title":"Int. J. Biol. Markers"},{"issue":"5258","key":"10.1016\/j.cca.2019.12.026_b0130","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1126\/science.272.5258.60","article-title":"Lymphocyte homing and homeostasis","volume":"272","author":"Butcher","year":"1996","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.cca.2019.12.026_b0135","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1006\/dbio.1996.0317","article-title":"The extracellular matrix in epithelial biology: shared molecules and common themes in distant phyla","volume":"180","author":"Ashkenas","year":"1996","journal-title":"Dev. Biol."},{"issue":"9\u201310","key":"10.1016\/j.cca.2019.12.026_b0140","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/BF01921740","article-title":"Role of laminin-nidogen complexes in basement membrane formation during embryonic development","volume":"51","author":"Dziadek","year":"1995","journal-title":"Experientia"},{"issue":"3","key":"10.1016\/j.cca.2019.12.026_b0145","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1134\/S0026893318030093","article-title":"Laminins in Metastatic Cancer","volume":"52","author":"Maltseva","year":"2018","journal-title":"Mol. Biol. (Mosk)."},{"issue":"2","key":"10.1016\/j.cca.2019.12.026_b0150","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/bies.950180208","article-title":"Supramolecular assembly of basement membranes","volume":"18","author":"Timpl","year":"1996","journal-title":"BioEssays News Rev. Mol. Cell Dev. Biol."},{"issue":"7","key":"10.1016\/j.cca.2019.12.026_b0155","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.molmed.2005.06.001","article-title":"Fibulins and cancer: friend or foe?","volume":"11","author":"Gallagher","year":"2005","journal-title":"Trends Mol. Med."},{"issue":"9","key":"10.1016\/j.cca.2019.12.026_b0160","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1054\/bjoc.2001.2078","article-title":"Laminin-1-induced migration of Multiple Myeloma cells involves the high-affinity 67 kD laminin receptor","volume":"85","author":"Vande Broek","year":"2001","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.cca.2019.12.026_b0165","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1021\/pr400881p","article-title":"Extracellular matrix remodeling by bone marrow fibroblast-like cells correlates with disease progression in Multiple Myeloma","volume":"13","author":"Slany","year":"2014","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.cca.2019.12.026_b0170","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.cca.2015.01.012","article-title":"Versican and its associated molecules: potential diagnostic markers for Multiple Myeloma","volume":"442","author":"Gupta","year":"2015","journal-title":"Clin. Chim. Acta Int. J. Clin. Chem."},{"issue":"6","key":"10.1016\/j.cca.2019.12.026_b0175","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1007\/s00432-019-02896-1","article-title":"Clinical significance of circulatory microRNA-203 in serum as novel potential diagnostic marker for Multiple Myeloma","volume":"145","author":"Gupta","year":"2019","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.cca.2019.12.026_b0180","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1080\/15476286.2019.1669405","article-title":"Targeting of stromal versican by miR-144\/199 inhibits Multiple Myeloma by downregulating FAK\/STAT3 signalling","volume":"17","author":"Gupta","year":"2020","journal-title":"RNA Biol."},{"issue":"21","key":"10.1016\/j.cca.2019.12.026_b0185","doi-asserted-by":"crossref","first-page":"3305","DOI":"10.1182\/blood-2014-02-554071","article-title":"TPL2 kinase regulates the inflammatory milieu of the myeloma niche","volume":"123","author":"Hope","year":"2014","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.cca.2019.12.026_b0190","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1182\/blood-2016-03-705780","article-title":"Immunoregulatory roles of versican proteolysis in the myeloma microenvironment","volume":"128","author":"Hope","year":"2016","journal-title":"Blood"},{"issue":"3\u20134","key":"10.1016\/j.cca.2019.12.026_b0195","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s10555-007-9094-7","article-title":"Tumour vascularization: sprouting angiogenesis and beyond","volume":"26","author":"Hillen","year":"2007","journal-title":"Cancer Metastasis Rev."},{"issue":"7070","key":"10.1016\/j.cca.2019.12.026_b0200","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/nature04478","article-title":"Angiogenesis in life, disease and medicine","volume":"438","author":"Carmeliet","year":"2005","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.cca.2019.12.026_b0205","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nm0195-27","article-title":"Angiogenesis in cancer, vascular, rheumatoid and other disease","volume":"1","author":"Folkman","year":"1995","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.cca.2019.12.026_b0210","first-page":"2597","article-title":"High expression of SDF-1 and VEGF is associated with poor prognosis in patients with synovial sarcomas","volume":"15","author":"Feng","year":"2018","journal-title":"Exp. Ther. Med."},{"issue":"1","key":"10.1016\/j.cca.2019.12.026_b0215","first-page":"171","article-title":"Expression of VEGF and Cox-2 in Patients with Esophageal Squamous Cell Carcinoma","volume":"19","author":"Luz","year":"2018","journal-title":"Asian Pac. J. Cancer Prev. APJCP"},{"issue":"1","key":"10.1016\/j.cca.2019.12.026_b0220","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00277-012-1572-5","article-title":"Interrelationship and expression profiling of cyclooxygenase and angiogenic factors in Indian patients with Multiple Myeloma","volume":"92","author":"Khan","year":"2013","journal-title":"Ann. Hematol."},{"issue":"8\u20139","key":"10.1016\/j.cca.2019.12.026_b0225","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.clinbiochem.2011.01.010","article-title":"Angiopoietin-2: a potential novel diagnostic marker in Multiple Myeloma","volume":"44","author":"Joshi","year":"2011","journal-title":"Clin. Biochem."},{"issue":"2","key":"10.1016\/j.cca.2019.12.026_b0230","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/labinvest.2011.162","article-title":"Bevacizumab attenuates major signaling cascades and eIF4E translation initiation factor in Multiple Myeloma cells","volume":"92","author":"Attar-Schneider","year":"2012","journal-title":"Lab. Investig. J. Tech. Methods Pathol."},{"issue":"3","key":"10.1016\/j.cca.2019.12.026_b0235","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.hermed.2016.04.001","article-title":"Cinnamon extract exhibits potent anti-proliferative activity by modulating angiogenesis and cyclooxygenase in myeloma cells","volume":"6","author":"Khan","year":"2016","journal-title":"J. Herb. Med."},{"key":"10.1016\/j.cca.2019.12.026_b0240","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/978-981-13-2835-0_9","article-title":"Telomerase and Ageing","volume":"90","author":"Telomeres","year":"2018","journal-title":"Subcell. Biochem."},{"key":"10.1016\/j.cca.2019.12.026_b0245","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1146\/annurev.genet.41.110306.130350","article-title":"How shelterin protects mammalian telomeres","volume":"42","author":"Palm","year":"2008","journal-title":"Annu. Rev. Genet."},{"issue":"7","key":"10.1016\/j.cca.2019.12.026_b0250","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1080\/10428194.2017.1387915","article-title":"Identifying the biomarker potential of telomerase activity and shelterin complex molecule, telomeric repeat binding factor 2 (TERF2), in Multiple Myeloma","volume":"59","author":"Kumar","year":"2018","journal-title":"Leuk. Lymphoma"},{"issue":"6","key":"10.1016\/j.cca.2019.12.026_b0255","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1007\/s11033-018-4409-z","article-title":"Novel combination of tanshinone I and lenalidomide induces chemo-sensitivity in myeloma cells by modulating telomerase activity and expression of shelterin complex and its associated molecules","volume":"45","author":"Kumar","year":"2018","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.cca.2019.12.026_b0260","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.lfs.2019.04.060","article-title":"Telomerase inhibitor MST-312 induces apoptosis of Multiple Myeloma cells and down-regulation of anti-apoptotic, proliferative and inflammatory genes","volume":"228","author":"Ameri","year":"2019","journal-title":"Life Sci."},{"issue":"4","key":"10.1016\/j.cca.2019.12.026_b0265","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/bjh.13067","article-title":"Quantification of clonal circulating plasma cells in relapsed Multiple Myeloma","volume":"167","author":"Gonsalves","year":"2014","journal-title":"Br. J. Haematol."},{"issue":"12","key":"10.1016\/j.cca.2019.12.026_b0270","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41408-018-0153-9","article-title":"Next generation flow for minimally-invasive blood characterization of MGUS and Multiple Myeloma at diagnosis based on circulating tumor plasma cells (CTPC)","volume":"8","author":"Sanoja-Flores","year":"2018","journal-title":"Blood Cancer J."},{"issue":"7","key":"10.1016\/j.cca.2019.12.026_b0275","doi-asserted-by":"crossref","first-page":"e0181447","DOI":"10.1371\/journal.pone.0181447","article-title":"Prognostic value of circulating plasma cells in patients with Multiple Myeloma: A meta-analysis","volume":"12","author":"Li","year":"2017","journal-title":"PLoS ONE"},{"issue":"10","key":"10.1016\/j.cca.2019.12.026_b0280","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1038\/leu.2014.98","article-title":"Quantification of clonal circulating plasma cells in newly diagnosed Multiple Myeloma: implications for redefining high-risk myeloma","volume":"28","author":"Gonsalves","year":"2014","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.cca.2019.12.026_b0285","doi-asserted-by":"crossref","first-page":"3646","DOI":"10.1182\/blood-2006-01-030015","article-title":"MicroRNAs: regulators of gene expression and cell differentiation","volume":"108","author":"Shivdasani","year":"2006","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.cca.2019.12.026_b0290","first-page":"213","article-title":"MicroRNA-based Cancer Therapeutics: Big Hope from Small RNAs","volume":"2","author":"Bhardwaj","year":"2010","journal-title":"Mol. Cell Pharmacol."},{"issue":"24","key":"10.1016\/j.cca.2019.12.026_b0295","doi-asserted-by":"crossref","first-page":"15524","DOI":"10.1073\/pnas.242606799","article-title":"Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia","volume":"99","author":"Calin","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"issue":"7043","key":"10.1016\/j.cca.2019.12.026_b0300","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/nature03702","article-title":"MicroRNA expression profiles classify human cancers","volume":"435","author":"Lu","year":"2005","journal-title":"Nature"},{"issue":"17","key":"10.1016\/j.cca.2019.12.026_b0305","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1182\/blood-2016-09-742296","article-title":"Prognostic role of circulating exosomal miRNAs in Multiple Myeloma","volume":"129","author":"Manier","year":"2017","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.cca.2019.12.026_b0310","first-page":"2131","article-title":"Serum miR-30d as a novel biomarker for Multiple Myeloma and its antitumor role in U266 cells through the targeting of the MTDH\/PI3K\/Akt signaling pathway","volume":"53","author":"Zhu","year":"2018","journal-title":"Int. J. Oncol."},{"issue":"9","key":"10.1016\/j.cca.2019.12.026_b0315","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.prp.2018.07.025","article-title":"miR-26b-5p suppresses proliferation and promotes apoptosis in Multiple Myeloma cells by targeting JAG1","volume":"214","author":"Jia","year":"2018","journal-title":"Pathol. Res. Pract."},{"issue":"8","key":"10.1016\/j.cca.2019.12.026_b0320","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1038\/s41375-019-0469-x","article-title":"Monitoring tumour burden and therapeutic response through analysis of circulating tumour DNA and extracellular RNA in Multiple Myeloma patients","volume":"33","author":"Mithraprabhu","year":"2019","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.cca.2019.12.026_b0325","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.3390\/ijms19071858","article-title":"Circulating Tumour DNA Analysis for Tumour Genome Characterisation and Monitoring Disease Burden in Extramedullary Multiple Myeloma","volume":"19","author":"Mithraprabhu","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.cca.2019.12.026_b0330","first-page":"806","article-title":"Multiple Myeloma and the Immune Microenvironment","volume":"17","author":"Kawano","year":"2017","journal-title":"Curr. Cancer Drug Targets"},{"issue":"9","key":"10.1016\/j.cca.2019.12.026_b0335","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1038\/leu.2014.108","article-title":"The targeting of immunosuppressive mechanisms in hematological malignancies","volume":"28","author":"Andersen","year":"2014","journal-title":"Leukemia"},{"issue":"Suppl","key":"10.1016\/j.cca.2019.12.026_b0340","doi-asserted-by":"crossref","first-page":"S185","DOI":"10.1016\/j.semcancer.2015.03.004","article-title":"Immune evasion in cancer: Mechanistic basis and therapeutic strategies","volume":"35","author":"Vinay","year":"2015","journal-title":"Semin. Cancer Biol."},{"issue":"5","key":"10.1016\/j.cca.2019.12.026_b0345","doi-asserted-by":"crossref","first-page":"920","DOI":"10.3109\/10428191003699563","article-title":"Dysregulation in T helper 1\/T helper 2 cytokine ratios in patients with Multiple Myeloma","volume":"51","author":"Sharma","year":"2010","journal-title":"Leuk. Lymphoma"},{"issue":"6","key":"10.1016\/j.cca.2019.12.026_b0350","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1080\/17474086.2019.1617128","article-title":"Potential of NK cells in Multiple Myeloma therapy","volume":"12","author":"Khan","year":"2019","journal-title":"Expert Rev. Hematol."},{"key":"10.1016\/j.cca.2019.12.026_b0355","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.omtm.2017.03.004","article-title":"Dendritic Cell Therapies for Hematologic Malignancies","volume":"5","author":"Weinstock","year":"2017","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.cca.2019.12.026_b0360","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2147\/JBM.S206459","article-title":"The immunomodulatory-drug, lenalidomide, sustains and enhances interferon-\u03b1 production by human plasmacytoid dendritic cells","volume":"10","author":"Kibata","year":"2019","journal-title":"J. Blood Med."},{"issue":"1","key":"10.1016\/j.cca.2019.12.026_b0365","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1182\/blood-2015-01-625004","article-title":"Lenalidomide augments actin remodeling and lowers NK-cell activation thresholds","volume":"126","author":"Lagrue","year":"2015","journal-title":"Blood"},{"issue":"1\u20132","key":"10.1016\/j.cca.2019.12.026_b0370","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0161-5890(02)00094-9","article-title":"CS1, a novel member of the CD2 family, is homophilic and regulates NK cell function","volume":"39","author":"Kumaresan","year":"2002","journal-title":"Mol. Immunol."},{"issue":"5","key":"10.1016\/j.cca.2019.12.026_b0375","doi-asserted-by":"crossref","first-page":"e266","DOI":"10.1111\/ajco.13033","article-title":"Increased exhausted CD8+ T cells with programmed death-1, T-cell immunoglobulin and mucin-domain-containing-3 phenotype in patients with Multiple Myeloma","volume":"14","author":"Tan","year":"2018","journal-title":"Asia Pac. J. Clin. Oncol."},{"issue":"19","key":"10.1016\/j.cca.2019.12.026_b0380","doi-asserted-by":"crossref","first-page":"12293","DOI":"10.1073\/pnas.192461099","article-title":"Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade","volume":"99","author":"Iwai","year":"2002","journal-title":"Proc. Natl Acad. Sci. U S A"},{"issue":"3","key":"10.1016\/j.cca.2019.12.026_b0385","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/hon.2636","article-title":"Plasma soluble programmed death ligand 1 levels predict clinical response in peripheral T-cell lymphomas","volume":"37","author":"Zhang","year":"2019","journal-title":"Hematol. Oncol."},{"issue":"11","key":"10.1016\/j.cca.2019.12.026_b0390","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1007\/s00262-014-1589-9","article-title":"FOXP3 and CTLA4 overexpression in multiple myeloma bone marrow as a sign of accumulation of CD4(+) T regulatory cells","volume":"63","author":"Braga","year":"2014","journal-title":"Cancer Immunol. Immunother. CII."},{"issue":"8","key":"10.1016\/j.cca.2019.12.026_b0395","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.4103\/0366-6999.155112","article-title":"Proteomic Analysis for Finding Serum Pathogenic Factors and Potential Biomarkers in Multiple Myeloma","volume":"128","author":"Zhang","year":"2015","journal-title":"Chin. Med. J. (Engl.)"},{"issue":"1","key":"10.1016\/j.cca.2019.12.026_b0400","first-page":"649","article-title":"Differential expression of serum proteins in Multiple Myeloma","volume":"17","author":"Ma","year":"2019","journal-title":"Exp. Ther. Med."},{"issue":"35","key":"10.1016\/j.cca.2019.12.026_b0405","doi-asserted-by":"crossref","first-page":"56726","DOI":"10.18632\/oncotarget.11059","article-title":"Comparative proteomic profiling of refractory\/relapsed Multiple Myeloma reveals biomarkers involved in resistance to bortezomib-based therapy","volume":"7","author":"Dytfeld","year":"2016","journal-title":"Oncotarget."},{"issue":"6","key":"10.1016\/j.cca.2019.12.026_b0410","first-page":"392","article-title":"Comparative proteomic profiling of sera from patients with refractory Multiple Myeloma reveals potential biomarkers predicting response to bortezomib-based therapy","volume":"127","author":"\u0141uczak","year":"2017","journal-title":"Pol. Arch. Intern. Med."},{"issue":"8","key":"10.1016\/j.cca.2019.12.026_b0415","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1002\/pmic.201000471","article-title":"A novel panel of protein biomarkers for predicting response to thalidomide-based therapy in newly diagnosed Multiple Myeloma patients","volume":"11","author":"Rajpal","year":"2011","journal-title":"Proteomics"},{"issue":"1","key":"10.1016\/j.cca.2019.12.026_b0420","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/hon.2391","article-title":"Bortezomib-induced peripheral neuropathy: A genome-wide association study on Multiple Myeloma patients","volume":"36","author":"Campo","year":"2018","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.cca.2019.12.026_b0425","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.3389\/fonc.2019.01056","article-title":"The Association of GSTT1, GSTM1, and TNF-\u03b1 Polymorphisms With the Risk and Outcome in Multiple Myeloma","volume":"9","author":"Zmorzy\u0144ski","year":"2019","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.cca.2019.12.026_b0430","doi-asserted-by":"crossref","first-page":"67","DOI":"10.21873\/anticanres.13080","article-title":"A Single Nucleotide Polymorphism in SLC7A5 Was Associated With Clinical Response in Multiple Myeloma Patients","volume":"39","author":"Poi","year":"2019","journal-title":"Anticancer Res."},{"issue":"11","key":"10.1016\/j.cca.2019.12.026_b0435","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1182\/blood-2018-10-880831","article-title":"High subclonal fraction of 17p deletion is associated with poor prognosis in Multiple Myeloma","volume":"133","author":"Thakurta","year":"2019","journal-title":"Blood"}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898119321953?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898119321953?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T14:51:05Z","timestamp":1757861465000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898119321953"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":87,"alternative-id":["S0009898119321953"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2019.12.026","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging biomarkers in Multiple Myeloma: A review","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2019.12.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}